From: Hodgkin Lymphoma Treatment (PDQ®)
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Prognostic Group | Treatment Options |
---|---|
Early favorable classic HL | Chemotherapy with or without radiation therapy |
Early unfavorable classic HL | Chemotherapy with or without radiation therapy |
Advanced classic HL | Chemotherapy |
Recurrent classic HL | Pembrolizumab or nivolumab (alone or with chemotherapy) |
Brentuximab vedotin | |
Brentuximab vedotin plus nivolumab | |
Chemotherapy with stem cell transplant | |
Combination chemotherapy | |
Radiation therapy | |
NLPHL | Watchful waiting/active surveillance |
Radiation therapy | |
Chemotherapy | |
Rituximab | |
HL during pregnancy | Watchful waiting |
Radiation therapy | |
Chemotherapy | |
HL = Hodgkin lymphoma; NLPHL = nodular lymphocyte-predominant Hodgkin lymphoma. |
From: Hodgkin Lymphoma Treatment (PDQ®)
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.